GlassScriptPhysician profile
Huiting Zhang
NPI 1679082416
$3,872.93
in general payments reported to CMS, 2019-2025
21 companies · $847 in 2025
The $847 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $964 · 2022: $638 · 2023: $302 · 2024: $1,121 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553 · Education: $718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,552.89 |
| Education | $717.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $587.79 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $552.91 | 2021-2025 | Keytruda, Welireg |
| Amgen INC. | $530.60 | 2021-2022 | |
| Janssen Biotech, INC. | $339.06 | 2023-2025 | Erleada, Akeega, Balversa |
| Gilead Sciences, INC. | $331.36 | 2021-2025 | |
| Abbvie INC. | $307.91 | 2021-2022 | |
| Eisai INC. | $245.85 | 2024-2025 | |
| Esperion Therapeutics, INC. | $218.62 | 2021-2022 | |
| Seagen INC. | $189.42 | 2023-2025 | Padcev |
| Astellas Pharma US INC | $99.99 | 2024 | |
| Novartis Pharmaceuticals Corporation | $97.85 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.17 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $49.88 | 2024-2025 | Lynparza |
| Janssen Pharmaceuticals, INC | $43.26 | 2021 | |
| Amarin Pharma, INC. | $40.84 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $28.54 | 2022 | |
| Tolmar, INC. | $28.07 | 2025 | Rubraca |
| Pharmaand Gmbh | $28.07 | 2025 | Rubraca |
| Takeda Pharmaceuticals U.S.A., INC. | $28.02 | 2021 | |
| Sumitomo Pharma America, INC. | $23.92 | 2024 | Orgovyx |
| Redhill Biopharma INC. | $21.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huiting Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.